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Audrey El-Gamil, 1 RESULTS: Hospitals will spend $221.27 (30.0%) more per PRT-treated apheresis PLT unit administered compared to a Zika-tested apheresis PLT unit that is irradiated and PGD tested in hospital. This difference is reflected in PRT PLT units having: 1) a higher hospital purchase price ($100.00 additional charge compared to an untreated PLT); 2) lower therapeutic effectiveness than untreated PLTs among hematologic-oncologic patients, which contributes to additional transfusions ($96.05); or 3) fewer PLT storage days, which contributes to higher outdating cost from expired PLTs ($67.87). Only a small portion of the incremental costs for PRT-treated PLTs are offset by costs that may be avoided, including primary bacterial culture, secondary bacterial testing ($26.65), hospital irradiation ($8.50), Zika testing ($4.47), and other costs ($3.03).
CONCLUSION:
The significantly higher cost of PRT-
treated PLTs over PGD-tested PLTs should interest stakeholders. For hospitals that outdate PLTs, savings associated with expiration extension to 7 days by adding PGD testing will likely be substantially greater than the cost of implementing PGD-testing. Our findings might usefully inform a hospital's decision to select a particular blood safety approach.
B acteria in platelets (PLTs) threaten patients and challenge physicians, scientists, and regulators to improve transfusion safety while preserving efficacy and availability. Bacteria pose the greatest risk of transfusion-transmitted disease in the United States. 1 Transfused apheresis PLTs have a bacterial contamination rate of approximately 1 in 1500 to 1 in 2747.
1,2
Passive surveillance does not detect most septic transfusion reactions. 3 The March 14, 2016, Food and Drug Administration (FDA) draft guidance emphasizes the need to enhance the safety and availability of PLTs. 1 Suggestions include the use of pathogen reduction technology (PRT) or a rapid 
MATERIALS AND METHODS
A model was developed to compare hospital acquisition, processing, and transfusion costs for apheresis PLTs that undergo PRT treatment with INTERCEPT to those untreated PLTs tested for bacteria with PGD. Costs for the two paths were translated into a bifurcated cost model accounting for all cost-related activities, starting from point of hospital purchase and ending with PLT transfusion.
An apheresis PLT baseline unit (leukoreduced [LR], nonirradiated) cost was identified. From this, mutually exclusive processing and associated costs were estimated and added to enable hospitals to compare the total cost of providing PLTs for transfusion that meet the recommendations of the FDA draft guidance for bacterial contamination risk mitigation.
To calculate cost per transfused PLT unit to a given hospital, we identified the cost-related activities that are: 1) built into the initial hospital acquisition price of a PLT unit, 2) incurred through in-hospital processing, and 3) associated with component transfusion. After these direct costs were computed, peer-reviewed literature was used to anticipate changes in hospital unit purchases that would be required to treat an equivalent patient population to equivalent outcomes with either PGD-tested or INTERCEPTtreated PLTs. Materially different unit purchases in INTERCEPT-treated and PGD-tested PLTs were expected due to: 1) different discard rates for PLT outdating under 5-day (INTERCEPT) and 7-day (PGD) storage, 2) PLT unit discards for true-/false-positive (TP/FP) test (PGD) results, and 3) the effect of PRT (INTERCEPT) on PLT degradation. Incremental unit purchases were allocated to a per PLT unit cost to facilitate an overall cost comparison of an INTERCEPT-treated PLT to an untreated PGD-tested PLT.
PLT acquisition
The hospital baseline apheresis PLT acquisition cost was determined from the AABB 2013 survey 4 We assumed that INTERCEPT treatment eliminates in-hospital processing for irradiation and secondary testing (through Day 5). 9 Both INTERCEPT-treated and PGDtested PLTs were presumed to accrue equivalent inhospital handling and issuance costs.
PLT administration
Both INTERCEPT-treated and PGD-tested PLTs accrue a per unit cost for administration of the PLT unit to a patient. We applied a cost for the inpatient administration of a unit of plasma identified in one study to that of a unit of PLTs, since we were unable to find an equivalent PLT cost. 15 This study also found that 16% of all PLTs transfused at the authors' hospital were given to outpatients. 15 We were unable to find outpatient specific administration cost data and therefore made no distinction between inpatient and outpatient PLT unit administration costs. There were no per-unit cost of administration differences assumed between INTERCEPT-treated and PGD-tested PLTs. There were, however, differences in total PLT and administration costs to cover the different unit purchases required between INTERCEPT-treated and PGD-tested PLTs to treat a hospital equivalent patient population to equivalent outcome.
Number of PLT units transfused
We identified three areas of difference in the number of PLTs purchased and transfused between PRT-treated and PGD-tested PLTs. They were: 1) outdate waste due to PLT expiry differences, 2) discards for positive PGD-tested PLTs, and 3) incremental purchase and transfusion due to PLT degradation from INTERCEPT treatment. Each of these cost impacts was allocated to a per-PLT-unit cost to facilitate comparison. A percentage of both INTERCEPT-treated and PGDtested PLTs will never be transfused because they expire past their FDA-allowable shelf-life of 5 and 7 days, respectively. 1 Rates of PLT wastage due to outdating after 5 and 7 days were identified in the published literature, which shows that the additional allowable transfusion days afforded to PGD-tested PLTs has the potential to markedly reduce outdate rates. 16, 17 There will be PGD-tested PLT unit discards for positive results (TP and FP). We applied a loss rate to PGDtested PLTs derived from published manufacturer specificity and literature. 2 The cost of PLT units testing positive and discarded were included. Notwithstanding the method used to apply a cost for discards due to positive results, it should be noted that as long as a hospital has an outdate rate that is greater than the combination of TP and FP rates, there will be little or no incremental cost for discarded units. The discarded unit would be replaced with a unit that would otherwise have been discarded as an outdated PLT. Purchase and transfusion of additional PLTs to adjust for PLT degradation induced by INTERCEPT treatment has been observed in randomized studies of hematologyoncology patients. [18] [19] [20] [21] [22] [23] [24] We used PLT loss rate from the FDA filing of INTERCEPT Summary of Safety and Efficacy Data (SSED) and published studies to quantify PLT degradation and applied this to the hematology-oncology patient population. [18] [19] [20] [21] [22] [23] [24] We used the SSED to quantify loss due to PLT degradation and only applied that loss rate to the subset of transfusion patients with hematologiconcologic disease. 8 
RESULTS

Hospital acquisition cost for apheresis PLTs
Our model builds from a nonirradiated apheresis LR PLT baseline cost assumption of $516.96, which was the mean amount paid per unit by US hospitals in 2013. 4 
PLT irradiation cost (blood centers and in hospital)
McCullough and coworkers 10 estimated the mean incremental cost for in-hospital irradiation of PLTs to be $8.50 per unit. We applied this amount to estimate cost for hospital-irradiated PLT units.
Hospital processing cost for secondary testing
The FDA draft guidance recommends apheresis PLTs be either secondary tested within 24 hours of transfusion after Day 3 or PRT treated after collection. Hospitals testing their PLTs with PGD will incur costs for purchasing the test device and the labor to perform it. The mean price paid for a PLT PGD Test is $26.50 (per test).
To calculate the labor cost associated with each PGD test performed, we assume that most PLT transfusions are performed in hospitals that will run PGD tests in batches of 6 or 12 PLT units. We conservatively estimate the labor time for an average batch of 9 PLT units by using the required time to run a batch of 24 units (60 min). 25 We assumed that technologists, a profession with an average national hourly rate of $38.70 (including benefits) according to BLS, 26 Table 1 and are consistent with field experience.
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Additional charge for pathogen reduction treatment
Although we were unable to identify a firm amount charged by blood centers to hospitals for PRT treatment, a range of an incremental $100 to $160 has been offered in literature. 30 We assumed the lowest end of this range and, further, that this amount covers all blood center costs unique to PRT treatment. We also assumed that the additional charge includes the impact of blood center cost savings for the elimination of irradiation, primary culture testing, and Zika testing and covers any mark-up required by the blood center. There were not sufficient data published to show PRT treatment cost breakdown; however, the type of services presumed to be included in a $100 PRT additional charge by blood centers to hospitals are outlined in Table 2 and warrant further investigation. PRTtreated PLTs would avoid in-hospital costs associated with irradiation and secondary testing (through Day 5).
9
Other in-hospital costs for PLTs
We assumed all apheresis PLTs (PGD-tested and INTER-CEPT-treated) accrue a $3.53 and $5.28 cost per unit for hospital blood bank handling and issuing PLTs to floor, respectively, based on activity-based cost estimates for fresh-frozen plasma.
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Incremental unit purchases for PLT efficacy degradation from PRT treatment
The PRT treatment process exposes PLTs to chemicals and ultraviolet light causing degradation of PLT efficacy.
18-24
The affected patient population and the extent of incremental PLT transfusions required to compensate for this degradation remain uncertain. We assumed that PRTtreated PLT degradation impacts the subset of hospital apheresis transfusions to hematologic-oncologic patients, which, in the United States in 2011, was reported to account for 34.4% of all transfusions. 8 A randomized controlled trial of PRT-treated compared to untreated PLTs administered to hematologic and cancer patients found 35.5% 18 more transfusions were needed when using PRTtreated PLTs. After weighting to the affected patient population, the overall effective PLT loss due to PRT degradation is 12.2% (i.e., 34.4% 3 35.5%). The inpatient cost of administering a PLT unit is an estimated $160.78 per unit. 15 This amount includes the cost of labor for administering and monitoring transfusions, as well as pre-and posttransfusion logistics. 15 Although 16% of all PLTs are delivered to outpatients, we were unable to find outpatient specific costs and therefore applied the inpatient rate to the universe of PLT transfusions. 15 Since the effects of PRT-treated PLT degradation were observed at the treatment level, the 12.2% (35.5% 3 34.4%) rate was applied to the PRT-treated unit cost inclusive of 
PLT unit purchase reduction enabled by PGD testing expiry extension to 7 days
The mean hospital apheresis PLT unit discard rate with 5-day storage was 11% in 2013. 4 Although efficiency studies of PLT outdating under the new 7-day rule were not available in time for this publication, a 2010 prospective pilot study investigating contamination rates for 7-day PLT storage observed an outdate rate of 1.55% (6039 of 388,903 units).
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As PRT-treated PLTs are currently regulated to 5-day storage, we applied the 2013 outdate rate of 0.11 4 to the per unit cost of a (nonadministered) PRT-treated PLT unit, $620.49, to determine a per-unit financial impact of outdating of $76.69. Thus, every PRT-treated PLT unit transfused by a given hospital accrues an additional cost of $76.69 to cover the cost of outdated discarded units. Applying this logic to PGD-tested, hospital-irradiated PLTs using a 7-day outdate rate of 0.0155 and the per-unit costs of (nonadministered) PLTs of $560.11 yields accrued perunit cost to cover discards of $8.82. PLT units discarded as a result of TP and FP PGD test results accrue separate costs. The sum of PGD TP and FP rates is applied to hospital-irradiated PLTs for an accrued cost of $2.98 ((0.0003 1 0.005) 3 $560.11). Additionally, for repeatedly reactive results, the PLT unit must be cultured. We allot $10.00 for this, which adds $0.05 to each PGD test ((0.0003 1 0.005) 3 $10.00). In total, there is an accrued per-unit cost of $3.03 to cover the units discarded because of TP/FP test results and culturing.
Fully loaded hospital cost difference of PGDtesting versus PRT-treating
PRT-treated PLTs would cost $221.27 ($959.29 -$738.02) more per PLT unit than PLTs that would be Zika tested before being irradiated and secondary tested in-hospital. There are three contributors to this difference. First, the additional charge for PRT treatment ($100.00 per unit) is 252% of the combined cost for Zika testing ($4.47), inhospital irradiating ($8.50), and secondary testing ($26.65). The second is that incremental PRT-treated PLTs will be required to treat an equivalent patient population due to PLT degradation. This increased transfusion requirement creates an allocation of $96.05 per PRTtreated PLT unit. Third, PRT-treated PLTs are limited to 5-day storage while PGD-tested (as a safety measure) can be stored up to 7 days. PRT-treated PLTs are allocated $67.87 ($76.69-$8.82) more per unit for outdate cost. The PGD testing economic advantage owing to outdate reduction is marginally offset by costs for discards and culturing ($3.03) associated with TP/FP results. The complete hospital cost differences are summarized in Table 3 . 
Limitations
We have not assigned costs for the increased adverse events associated with PRT treatment reported in the SPRINT trial 31 and described in the FDA INTERCEPT SSED 18 or for the reduction in split rates and absence of triple collections with PRT treatment. Our analysis has presumed that hospitals will use 100% PRT-treated or 100% PGD-tested PLTs. It may not be feasible, particularly initially, for a hospital to obtain an inventory of 100% PRTtreated PLTs. We have not accounted for a hospital using a dual inventory in our analysis. A complete list of limitations is in Table 4 .
DISCUSSION
Few studies have shown the impact of these different technologies on hospital costs. We compared the mean hospital cost per transfusion for an INTERCEPT PRTtreated PLT unit to a Zika-tested PLT unit that is irradiated and PGD tested in hospital (Table 3) . Regardless of whether PLTs are nonirradiated or irradiated (at the blood center or at the hospital), PLTs that are PGD tested are substantially more economical for hospitals to use than PRT-treated PLTs. We found that hospitals would accrue an additional cost of $221.27 per PRT-treated PLT transfusion compared to the aforementioned PGD-tested unit. If a hospital receives PLTs irradiated at the collection establishment, it can add the additional cost when calculating the differential; if the component is not irradiated, it can subtract the cost attributable to irradiation (in our calculation $8.50). The final cost difference incorporates all costs avoided by PRT treatment.
Degradation
PGD testing is performed on a sample from a segment that would otherwise not be transfused and has no adverse effect on PLT quality or quantity. Although PRT effectively eliminates the transmission of a broad array of microbial contaminants, this process results in substantial PLT loss, dilution, and degradation. [18] [19] [20] [21] [22] [23] [24] The FDA SSED for
INTERCEPT describes radiolabeling studies demonstrating a 15% to 22% decrease in PLT recovery and a 20% to 25% decrease in PLT survival of INTERCEPT-treated PLTs compared to untreated PLTs. 18 The clinical impact of diminished PLT recovery and survival is significant in hematology and oncology populations. 20, 23, 24 In these populations, studies have found that patients transfused with PRT-treated PLTs require more units compared to patients who received untreated PLTs. [18] [19] [20] [21] [22] [23] [24] 32 The potential clinical impact in other patient populations has not been studied. The economic impact of acquiring and transfusing incremental PLT units to compensate for PRT degradation is significant, as a sizable proportion (34.4%) of all apheresis PLTs transfused in the United States are administered to hematologic-oncologic patients. 8 Randomized controlled trials in these patients have detected increased days of Grade 2 bleeding and an increased incidence of Grade 2 bleeding in patients receiving PRT PLTs compared to patients receiving untreated PLTs. [18] [19] [20] 24 Radiolabeling studies summarized by Ramsey found the immediate posttransfusion recoveries of PRT-treated PLTs stored for 5 days was 74% to 84% that of untreated PLTs, and posttransfusion life spans of PRT-treated PLTs stored for 5 days was 4 to 5 days, compared to 6 to 7 days for untreated PLTs. 22 There are no data to indicate whether increased PLT transfusions would be required owing to decreased efficacy of non-PRT PLTs stored for 7 days compared to those stored for 5 days or fewer. Because only approximately 11% of PLTs would be stored more than 5 days, the cost impact, if any, will be minimal.
Some state the decreased corrected count increments with transfusion of PRT PLTs is not a particular concern owing to the findings of the PLADO study 33 in which lower PLT doses were not associated with inferior outcomes. If this is accepted, then the corollary for untreated PLTs is that dosing is excessive and could be reduced to accrue economic benefit.
Effect of 7-day storage
PLTs expiring past their FDA allowable shelf life are discarded. In 2015, the FDA approved increasing the shelf life of PGD-tested apheresis PLTs in plasma from 5 to 7 days. 1 INTERCEPT PLTs remain regulated to 5-day storage. Two additional storage days has a marked effect on rates of discarded PLTs. The US DHHS National Blood Collection and Utilization Survey from 2011 found 12.8% of all processed PLTs expire after 5-day storage. 8 A comparable rate of 11.0% was reported by the AABB in 2013. 4 A US study published in 2010 observed a 7-day outdate rate of 1.55% among bacterially tested apheresis PLTs. The reported outdate rate at the University of North Carolina Medical Center dropped from a 5-day-stored PLT outdate rate of 2.9% to 1.3% with a 7-day outdate. 16, 17 The University of Vermont Medical Center had a historical mean PLT outdate rate of 24% with a 5-day outdate that decreased to 12% in the first 3 months after implementing a 7-day outdate (S.K. Harm, personal experience). Dunbar and coworkers 34 at Dartmouth-Hitchcock Medical Center reported a 5-day outdate rate of 8.7% that decreased to 1.7% over the first 4 months after implementation of a 7-day outdate (N. Dunbar, personal communication, December 2, 2016 ). In our model, lowering hospitals' PLT outdate rates by extending shelf life dramatically improved the economic benefit of PGD-tested over PRT-treated PLTs. Increasing the PLT shelf-life to 7 days could also significantly reduce collection costs (weekends and holidays) and is worth further investigation.
In conclusion, PRT treatment creates a significant increase in hospital costs through both a higher unit purchase price and the need to purchase more PLTs owing to decreased PLT recovery and survival posttransfusion. PRTtreated PLTs add costs with no opportunity to extend dating. We calculate the mean incremental cost difference is $221.27 per unit more for a PRT-treated PLT unit compared to a Zika-tested PLT unit irradiated and PGD tested in hospital. If an institution chooses to use PLTs only through Day 5, the incremental cost difference is $160.86 (calculations not shown, available on request). We provide a model in which hospitals can enter their own costs and calculate the cost difference they will experience. If a hospital's PLT acquisition cost times the PLT outdate rate is greater than the cost of PGD testing (Table 1) , then implementing PGD testing is cost saving. This analysis can help inform a hospital's decision regarding which FDA-guided option better serves their requirements.
